Trial Profile
A Phase II Study of Eribulin (NSC 707389) in Recurrent or Refractory Osteosarcoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Jul 2021
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications Osteosarcoma
- Focus Therapeutic Use
- 08 Jun 2021 Results (n=57) of NCT02097238, NCT02470091 and NCT02487979 assessing efficacy patients with recurrent/refractory osteosarcoma, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
- 04 May 2020 Status changed from active, no longer recruiting to completed.
- 19 Mar 2020 Status changed from completed to active, no longer recruiting.